Abstract
Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Keywords: Allergy, RNAi, siRNA, shRNA, gene therapy, transcription factor, cytokine, susceptibility genes
Current Gene Therapy
Title: RNA Interference: New Therapeutics in Allergic Diseases
Volume: 8 Issue: 4
Author(s): Chen-Chen Lee and Bor-Luen Chiang
Affiliation:
Keywords: Allergy, RNAi, siRNA, shRNA, gene therapy, transcription factor, cytokine, susceptibility genes
Abstract: Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Export Options
About this article
Cite this article as:
Lee Chen-Chen and Chiang Bor-Luen, RNA Interference: New Therapeutics in Allergic Diseases, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160692
DOI https://dx.doi.org/10.2174/156652308785160692 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Advances in CAR-T Cell Therapy and CRISP combination
CAR-T cell therapy is a groundbreaking immunotherapy that has transformed cancer treatment, particularly in hematological malignancies like leukemia and lymphoma. It involves engineering a patient’s own T cells to express chimeric antigen receptors (CARs) that target and destroy cancer cells. The therapy has demonstrated remarkable success, achieving durable remissions in ...read more
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Lipid Nanocarriers as an Alternative for the Delivery of Bioactive Compounds Beneficial to Health
Current Bioactive Compounds Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Role of Protein Phosphatase 2A in Alzheimers Disease
Current Alzheimer Research AMPK Function in Aging Process
Current Drug Targets Mitochondrial Medicine: A Promising Therapeutic Option Against Various Neurodegenerative Disorders
Current Neuropharmacology Neurodegenerative Disorders Treatment: The MicroRNA Role
Current Gene Therapy Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Editorial [ Neurodegenerative Disorders: From Molecules to Man (Part 2) Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito ]
CNS & Neurological Disorders - Drug Targets Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Editorial (Thematic Issue: Current Update on Association Between Alzheimer’s Disease and Type 2 Diabetes: Volume I)
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Selection: Mitochondrial Dysfunction & Neurological Disorders)
Current Neuropharmacology Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets